CARM
Carisma Therapeutics Inc.
- PER (TTM)
- 0.00
- PER (Forward)
- -0.00
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- -0.02
- 시가총액
- 20,922
- 배당수익률
- -
- 베타
- 1.31
- 1개월 수익률
- -98.40%
- 3개월 수익률
- -98.91%
- 6개월 수익률
- -99.00%
- 1년 수익률
- -99.77%
- 2년 수익률
- -
- 5일 평균거래량
- 20714
- 60일 평균거래량
- 68622
- 1년 평균거래량
- 5925887
- 5d/60d 거래량 비율
- 0.30×
- 60d/1y 거래량 비율
- 0.01×
- 변동성(60일, 연환산)
- 680.80%
- BB 스퀴즈 스코어
- 5.49
- SMA50 비율
- 0.02
- SMA200 비율
- 0.00
- RSI (14)
- 15
- 20일 수렴도
- 1.53
- 52주 최고
- 1.11
- 52주 최저
- 0.00
- 고점 대비
- -99.95%
- 저점 대비
- 400.00%
펀더멘털 갱신: 2026-05-10T08:11:36+00:00 · 시세 갱신: 2026-05-10T06:16:03+00:00
회사 정보
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.